PA
SBRA icon

PharVision Advisers’s Sabra Healthcare REIT SBRA Stock Holding History

PharVision Advisers’s Portfolio SBRA Stock Details SBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,025
Closed -$280K – 969
2025
Q3 		$280K Buy
+15,025
New +$281K 0.16% 265

Other funds holding SBRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
EGM
Engineers Gate Manager New York $7.71B AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PharVision Advisers's SBRA Position: Q4 2025 in Review

PharVision Advisers sold out of Sabra Healthcare REIT (SBRA) in Q4 2025, closing a stake of 15,025 shares — an estimated $280K sold.

PharVision Advisers first reported a position in SBRA in Q3 2025 and held it in 1 quarter. The position peaked at $280K in Q3 2025. 440 funds tracked by Wall St. Rank hold SBRA as of Q4 2025.

  • PharVision Advisers reported no remaining Sabra Healthcare REIT position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 15,025 Sabra Healthcare REIT shares in Q4 2025, an estimated $280K.
  • PharVision Advisers first reported a position in Sabra Healthcare REIT in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Sabra Healthcare REIT position peaked at $280K in Q3 2025.
  • 440 funds tracked by Wall St. Rank held Sabra Healthcare REIT as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.